Tags

Type your tag names separated by a space and hit enter

Calcitonin gene-related peptide targeted immunotherapy for migraine: progress and challenges in treating headache.
BioDrugs. 2014 Jun; 28(3):237-44.B

Abstract

A role for calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine has been established over the past 25 years. There have now been at least five different small-molecule CGRP antagonists that have demonstrated statistical proof of efficacy in the acute treatment of migraine. At present, multiple clinical trials are underway that are assessing the ability of long-acting antibodies against CGRP to prevent frequent migraine attacks. This review summarizes the existing data concerning the role of CGRP in migraine and attempts to highlight some possible outcomes from the ongoing anti-CGRP antibody trials.

Authors+Show Affiliations

, 24660 Cabrillo Street, Carmel, CA, 93923, USA, drperoutka@gmail.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24452707

Citation

Peroutka, Stephen J.. "Calcitonin Gene-related Peptide Targeted Immunotherapy for Migraine: Progress and Challenges in Treating Headache." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, vol. 28, no. 3, 2014, pp. 237-44.
Peroutka SJ. Calcitonin gene-related peptide targeted immunotherapy for migraine: progress and challenges in treating headache. BioDrugs. 2014;28(3):237-44.
Peroutka, S. J. (2014). Calcitonin gene-related peptide targeted immunotherapy for migraine: progress and challenges in treating headache. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 28(3), 237-44. https://doi.org/10.1007/s40259-014-0083-4
Peroutka SJ. Calcitonin Gene-related Peptide Targeted Immunotherapy for Migraine: Progress and Challenges in Treating Headache. BioDrugs. 2014;28(3):237-44. PubMed PMID: 24452707.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Calcitonin gene-related peptide targeted immunotherapy for migraine: progress and challenges in treating headache. A1 - Peroutka,Stephen J, PY - 2014/1/24/entrez PY - 2014/1/24/pubmed PY - 2015/6/11/medline SP - 237 EP - 44 JF - BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy JO - BioDrugs VL - 28 IS - 3 N2 - A role for calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine has been established over the past 25 years. There have now been at least five different small-molecule CGRP antagonists that have demonstrated statistical proof of efficacy in the acute treatment of migraine. At present, multiple clinical trials are underway that are assessing the ability of long-acting antibodies against CGRP to prevent frequent migraine attacks. This review summarizes the existing data concerning the role of CGRP in migraine and attempts to highlight some possible outcomes from the ongoing anti-CGRP antibody trials. SN - 1179-190X UR - https://www.unboundmedicine.com/medline/citation/24452707/Calcitonin_gene_related_peptide_targeted_immunotherapy_for_migraine:_progress_and_challenges_in_treating_headache_ L2 - https://dx.doi.org/10.1007/s40259-014-0083-4 DB - PRIME DP - Unbound Medicine ER -